Table 8Comparison of low dose and standard dose results

5 μg BID10 μg BIDPlacebo
De Fronzo
 HbA1c change− 0.4%− 0.8%
 % reaching < 7%32%46%13%
 weight− 1.6kg−2.8 kg−0.3kg
Kendall
 HbA1c change− 0.55%− 0.77%+ 0.23%
% <7%24%30%7%

From: 2, The glucagon-like peptide-1 analogue; exenatide

Cover of Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement)
Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement) [Internet].
NICE Clinical Guidelines, No. 87S.
Waugh N, Cummins E, Royle P, et al.
Copyright © 2009, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.